Literature DB >> 26795248

The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation.

David Michonneau1, Pervinder Sagoo2, Béatrice Breart2, Zacarias Garcia2, Susanna Celli2, Philippe Bousso3.   

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for hematologic malignancies, relies on donor cytotoxic T lymphocyte (CTL)-mediated graft-versus-leukemia (GVL) effect. Major complications of HSCT are graft-versus-host disease (GVHD) that targets specific tissues and tumor relapses. However, the mechanisms dictating the anatomical features of GVHD and GVL remain unclear. Here, we show that after HSCT, CTLs exhibited different killing activity in distinct tissues, being highest in the liver and lowest in lymph nodes. Differences were imposed by the microenvironment, partly through differential PD-1 ligand expression, which was strongly elevated in lymph nodes. Two-photon imaging revealed that PD-1 blockade restored CTL sensitivity to antigen and killing in lymph nodes. Weak CTL activity in lymph nodes promoted local tumor escape but could be reversed by anti-PD-1 treatment. Our results uncover a mechanism generating an anatomical segregation of CTL activity that might dictate sites of GVHD and create niches for tumor escape.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26795248     DOI: 10.1016/j.immuni.2015.12.008

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  35 in total

Review 1.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

2.  Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells.

Authors:  Hung Nguyen; Sandeepkumar Kuril; David Bastian; Jisun Kim; Mengmeng Zhang; Silvia G Vaena; Mohammed Dany; Min Dai; Jessica Lauren Heinrichs; Anusara Daenthanasanmak; Supinya Iamsawat; Steven Schutt; Jianing Fu; Yongxia Wu; David P Fairlie; Carl Atkinson; Besim Ogretmen; Stephen Tomlinson; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2018-12-20

3.  PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Authors:  Beatrice Casadei; Alessandro Broccoli; Vittorio Stefoni; Cinzia Pellegrini; Miriam Marangon; Alice Morigi; Laura Nanni; Ginevra Lolli; Matteo Carella; Lisa Argnani; Michele Cavo; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

4.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

Review 5.  Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Authors:  Matthew J Pianko; Aaron D Goldberg; Alexander M Lesokhin
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

6.  CD8+ T Cells Lack Local Signals To Produce IFN-γ in the Skin during Leishmania Infection.

Authors:  Fernanda O Novais; Andrea C Wong; Daniel O Villareal; Daniel P Beiting; Phillip Scott
Journal:  J Immunol       Date:  2018-01-24       Impact factor: 5.422

7.  A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Caitlin Costello; Alex F Herrera; Frederick L Locke; Rodrigo O Maegawa; Alexandra Savell; Michael Mazzeo; Adrienne Anderson; Alexander P Boardman; Augustine Weber; David Avigan; Yi-Bin Chen; Sarah Nikiforow; Vincent T Ho; Corey Cutler; Edwin P Alyea; Pavan Bachireddy; Catherine J Wu; Jerome Ritz; Howard Streicher; Edward D Ball; Asad Bashey; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2020-06-11       Impact factor: 22.113

8.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

9.  Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.

Authors:  Jian-Ming Li; Christopher T Petersen; Jing-Xia Li; Reema Panjwani; Daniel J Chandra; Cynthia R Giver; Bruce R Blazar; Edmund K Waller
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

10.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.